Emergent Biosolutions Begins Phase 1B Study of Potential Dengue Cure

Emergent Biosolutions Inc pic

Emergent Biosolutions Inc
Image: emergentbiosolutions.com

Business executive Fuad El-Hibri leads the board of trustees of El-Hibri Foundation, an organization focused on promoting peace and inclusivity in a diverse society. Besides his philanthropic work, Fuad El-Hibri chairs the board of directors of global biopharmaceutical company Emergent Biosolutions Inc.

In February 2017, Emergent Biosolutions Inc. announced it was beginning a Phase 1b study to assess how safe and tolerable UV-4B was. UV-4B is an antiviral under development as a potential treatment for the dengue virus. It works by targeting host glycosidase enzymes to reduce virus infectivity. If the trials are ultimately successful, the host-based action mechanism can be re-applied across a broad spectrum to treat other diseases such as SARS, Zika, and influenza.

Emergent’s Phase 1b study will enroll 40 adults from different US sites. The study is funded by the National Institute of Health’s Department of Health Human Services.

The Center for Disease Control estimates there are 100 countries affected by the deadly dengue epidemic, many of them in the tropics. These countries report up to 400 million new dengue infections annually, and there is no known cure for the disease.


The El-Hibri Foundation Honors Deserving Students with Scholarships


El-Hibri Foundation pic

El-Hibri Foundation
Image: elhibrifoundation.org

Capitalizing on his extensive experience in the biopharmaceutical industry, Fuad El-Hibri founded Emergent BioSolutions Inc. in 1998. Focused on developing and commercializing vaccines for disease prevention, Emergent achieved widespread international success under Fuad El-Hibri’s leadership, marketing the only anthrax vaccine to receive FDA approval. Outside of healthcare, Fuad El-Hibri is also committed to improving relations for Muslims in America. He created the El-Hibri Foundation to help with that effort.

As part of its Peace Awards program, the El-Hibri Foundation presents three $5,000 scholarships to students each year. The recipients are chosen based on their efforts at increasing Muslim inclusion in the United States. The aim of the scholarship is to support emerging leaders for their work and to foster peace and unity across the country.

To be eligible for the scholarship, students must be U.S. citizens who demonstrate the courage of their convictions in working toward American Muslim inclusion and understanding. Such courage can be shown by organizing events to promote unity and diversity, taking a stand to challenge prejudice and Islamophobia, creating activities that bring together those of diverse faiths, and otherwise collaborating to advance peaceful relations among those of different religions. Each applicant must also be currently enrolled as an undergraduate or graduate student in a college or university and fulfill the application requirements.

For scholarship consideration, applicants are required to submit three 250-word essays explaining their professional goals, the inspiration for their work, and why it is important to them. They must also provide a copy of their CV, a college transcript, one letter of reference from a professor or advisor, and another letter of reference from a past or current supervisor or mentor.

Winners for the 2016-2017 school year were honored at a ceremony on October 27, 2016. For more information about the El-Hibri Foundation scholarship and the Peace Awards, visit www.elhibrifoundation.org.

Yale Healthcare Conference Encourages Discussion of Healthcare Issues


Fuad El-Hibri Supports Biomedical Research Alliance

Fuad El-Hibri is the founder and executive chairman of the board of Emergent BioSolutions, Inc., of Rockville, Maryland. In this role, Fuad El-Hibri has maintained sales and profitability in the manufacture of vaccines for tuberculosis and influenza. Seeking to encourage further progress in basic and translational research, Mr. El-Hibri serves on the board of trustees of the International Biomedical Research Alliance.

The International Biomedical Research Alliance is a multidisciplinary group whose members include the National Institutes of Health, Cambridge University, and Oxford University. The alliance’s Scholars Program brings in students from the United States and Europe to conduct research with experts in the member institutions. The four-year endeavor enables students to pursue research agendas in the United States and the United Kingdom.

The scholars thrive in a results-oriented culture that promotes accessibility and permits them to work in open collaboration. They work with mentors who often come from biomedicine and other fields, such as mathematics and physics. This process frequently produces new discoveries, and every graduate of the program has single-authored one or more peer-reviewed articles.